Comprehensive pan-cancer analysis reveals prognostic implications of TMEM92 in the tumor immune microenvironment
- PMID: 38642258
- DOI: 10.1007/s12094-024-03477-6
Comprehensive pan-cancer analysis reveals prognostic implications of TMEM92 in the tumor immune microenvironment
Abstract
Background: Transmembrane protein 92 (TMEM92) has been implicated in the facilitation of tumor progression. Nevertheless, comprehensive analyses concerning the prognostic significance of TMEM92, as well as its role in immunological responses across diverse cancer types, remain to be elucidated.
Methods: In this study, data was sourced from a range of publicly accessible online platforms and databases, including TCGA, GTEx, UCSC Xena, CCLE, cBioPortal, HPA, TIMER2.0, GEPIA, CancerSEA, GDSC, exoRBase, and ImmuCellAI. We systematically analyzed the expression patterns of TMEM92 at both mRNA and protein levels across diverse human organs, tissues, extracellular vesicles (EVs), and cell lines associated with multiple cancer types. Subsequently, analyses were conducted to determine the relationship between TMEM92 and various parameters such as prognosis, DNA methylation, copy number variation (CNV), the tumor microenvironment (TME), immune cell infiltration, genes with immunological relevance, tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair (MMR), and half-maximal inhibitory concentration (IC50) values.
Results: In the present study, we observed a pronounced overexpression of TMEM92 across a majority of cancer types, which was concomitantly associated with a less favorable prognosis. A notable association emerged between TMEM92 expression and both DNA methylation and CNV. Furthermore, a pronounced relationship was discerned between TMEM92 expression, the TME, and the degree of immune cell infiltration. Intriguingly, while TMEM92 expression displayed a positive correlation with macrophage presence, it inversely correlated with the infiltration level of CD8 + T cells. Concurrently, significant associations were identified between TMEM92 and the major histocompatibility complex, TMB, MSI, and MMR. Results derived from Gene Set Enrichment Analysis and Gene Set Variation Analysis further substantiated the nexus of TMEM92 with both immune and metabolic pathways within the oncogenic context.
Conclusions: These findings expanded the understanding of the roles of TMEM92 in tumorigenesis and progression and suggest that TMEM92 may have an immunoregulatory role in several malignancies.
Keywords: Alteration; Immunity; Pan-cancer; Prognosis; TMEM92; Tumor microenvironment.
© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Similar articles
-
Pan-cancer analysis shows that BCAP31 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types.Front Immunol. 2024 Dec 16;15:1507375. doi: 10.3389/fimmu.2024.1507375. eCollection 2024. Front Immunol. 2024. PMID: 39737177 Free PMC article.
-
Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.Front Immunol. 2022 Jan 6;12:812713. doi: 10.3389/fimmu.2021.812713. eCollection 2021. Front Immunol. 2022. PMID: 35069601 Free PMC article.
-
An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.J Cancer. 2023 Jun 19;14(10):1809-1836. doi: 10.7150/jca.84454. eCollection 2023. J Cancer. 2023. PMID: 37476180 Free PMC article.
-
Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis.Front Immunol. 2022 Sep 21;13:977016. doi: 10.3389/fimmu.2022.977016. eCollection 2022. Front Immunol. 2022. PMID: 36211383 Free PMC article.
-
Exploring the Complexity of Pan-Cancer: Gene Convergences and in silico Analyses.Breast Cancer (Dove Med Press). 2024 Dec 13;16:913-934. doi: 10.2147/BCTT.S489246. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 39691553 Free PMC article. Review.
References
-
- Global Burden of Disease Cancer C, Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8(3):420–44. https://doi.org/10.1001/jamaoncol.2021.6987 .
-
- Saw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer. 2022;8(7):527–55. https://doi.org/10.1016/j.trecan.2022.03.001 . - DOI - PubMed
-
- Schmit K, Michiels C. TMEM proteins in cancer: a review. Front Pharmacol. 2018;9:1345. https://doi.org/10.3389/fphar.2018.01345 . - DOI - PubMed - PMC
-
- Zhao Y, Zhang K, Pan H, Wang Y, Zhou X, Xiang Y, et al. Genetic analysis of six transmembrane protein family genes in Parkinson’s disease in a large Chinese cohort. Front Aging Neurosci. 2022;14: 889057. https://doi.org/10.3389/fnagi.2022.889057 . - DOI - PubMed - PMC
-
- Hayez A, Malaisse J, Roegiers E, Reynier M, Renard C, Haftek M, et al. High TMEM45A expression is correlated to epidermal keratinization. Exp Dermatol. 2014;23(5):339–44. https://doi.org/10.1111/exd.12403 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials